Canaccord lowered the firm’s price target on Prestige Consumer (PBH) to $72 from $86 and keeps a Buy rating on the shares. The firm updated its model following its Q4 miss which was driven primarily by continued eye care weakness coupled with incremental pressure from the Iran conflict.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Balances Setbacks With Growth Plan
- Prestige Consumer falls -14.0%
- Oppenheimer downgrades Prestige Consumer following weaker results, guidance
- Prestige Consumer downgraded to Perform from Outperform at Oppenheimer
- Prestige Consumer Healthcare Issues Fiscal 2026 Results, Outlook